Additional studies are needed to determine whether SGLT2 inhibitors can meaningfully delay kidney disease progression in people with non-albuminuric or non-proteinuric DKD
However, vertical SG does not directly activate FXR in the liver or intestine
How clinicians currently interpret the evidence Clinicians balance the low frequency of serious events in population data with scattered individual reports of intolerance
Do not use Zepbound if you or your family have a history of thyroid cancer, like MTC or MEN 2
DOI: Published online: November 8, 2021 1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 2 Asan Diabetes Center, Asan Medical Center, Seoul, Korea 3 Department of Internal Medicine, H Plus Yangji Hospital, Seoul, Korea Corresponding author: Woo Je Lee Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea E-mail: [email protected] *Hwi Seung Kim and Taekwan Yoon contributed equally to this study as first authors
